| Toggle Summary
|
Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates
Patient Enrollment Progress During 2015 Confirms Timeline Expectations for Topline Data Availability From Four Trials in First Half of 2016
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to Its Board of Directors
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
Patient Recruitment Ongoing in Trials in Insomnia Disorder and Adjunctive Major Depressive Disorder
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Baird 2015 Healthcare Conference on September 9, 2015
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report Second Quarter 2015 Financial Results and Host Conference Call on August 5, 2015
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
|
View HTML
|
